Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer.
To value the late genitourinary (GU) morbidity in men treated with a hypofractionated radiotherapy regimen for prostate cancer. Patients with intermediate risk factors according to D'Amico's criteria were selected. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy. Significant changes in storage-symptoms were not found. A significant transient worsening in the score of late effects of normal tissue late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain was observed at 12 months with subsequent improvement at 28 months. The assessment of voiding-symptoms and maximum urinary flow rate (Qmax) showed that no significant difference was measurable at 12 and 28 months. For PVR, a transient increase at 12 months with a subsequent decrease at 28 months was measured. No significant increase in alpha-blockers usage and in the percentage of men with pathological nonintubated uroflowmetry (NIF) was observed at 12 and 28 months. Finally, patients did not perceive any clinical worsening in their quality of life (QoL) as attested by the International Prostate Symptom Score (IPSS)-QoL. Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results.
Tombolini
V
V
Department of Experimental Medicine, Division of Radiotherapy, University of L'Aquila, L'Aquila, Italy.
Di Staso
M
M
Bonfili
P
P
Di Genesio Pagliuca
M
M
Franzese
P
P
Buonopane
S
S
Valeriani
M
M
Maurizi Enrici
R
R
Festuccia
C
C
Gravina
G L
GL
D000368:Aged; D000813:Anilides / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011788:Quality of Life; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods; D014105:Tosyl Compounds / Q000627:therapeutic use; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology* / Q000503:physiopathology; D014566:Urogenital System / Q000473:pathology*
D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D016729:Leuprolide